CD8A and neoplasm: Among the various ICB therapeutic strategies, T cells, especially CD8+ T cells, serve as the primary targets for mediating anti-tumor immunity owing to their direct ability to kill tumor cells (Hudson and Wieland, 2023; Robert, 2020).